HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael S Ip Selected Research

Retinal Vein Occlusion

12/2022Anatomic Biomarkers of Macular Edema Associated with Retinal Vein Occlusion.
3/2022Disease-modifying effects of ranibizumab for central retinal vein occlusion.
1/2022Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
12/2021Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
1/2021Ellipsoid Zone Defects in Retinal Vein Occlusion Correlates With Visual Acuity Prognosis: SCORE2 Report 14.
1/2021SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.
1/2020A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study.
12/2019Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
8/2019Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.
1/2019Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael S Ip Research Topics

Disease

42Macular Edema
12/2022 - 09/2002
34Retinal Vein Occlusion
12/2022 - 09/2002
14Diabetic Retinopathy (Retinopathy, Diabetic)
01/2022 - 09/2007
5Hemorrhage
03/2022 - 09/2009
3Retinal Hemorrhage
03/2022 - 09/2010
3Endophthalmitis (Ophthalmia)
05/2017 - 09/2007
3Macular Degeneration (Age-Related Maculopathy)
09/2014 - 10/2008
3Cataract (Cataracts)
12/2009 - 03/2009
2Glaucoma
12/2021 - 12/2009
2Atrophy
10/2021 - 11/2006
2Stargardt Disease
10/2021 - 01/2020
2Choroidal Neovascularization
01/2017 - 03/2013
2Burns
01/2017 - 03/2013
2Papilledema
12/2014 - 01/2011
2Vitreous Hemorrhage
09/2012 - 12/2009
1Microaneurysm
01/2021
1Infertility (Sterility)
09/2019
1Retinal Neovascularization
01/2018
1Angle-Closure Glaucoma (Glaucoma, Angle Closure)
05/2017
1Diabetes Mellitus
01/2017
1Hypertension (High Blood Pressure)
01/2017
1Coronary Artery Disease (Coronary Atherosclerosis)
01/2017
1Disease Progression
09/2012
1Dyslipidemias (Dyslipidemia)
01/2011
1Inflammation (Inflammations)
09/2010
1Edema (Dropsy)
05/2010
1Telangiectasis (Telangiectasia)
01/2010
1Retinoschisis (Retinoschisis, Juvenile)
12/2008
1Retinal Perforations
12/2008
1Retinal Detachment (Retinal Detachments)
12/2008

Drug/Important Bio-Agent (IBA)

25Retinaldehyde (Retinal)IBA
01/2022 - 11/2006
16afliberceptIBA
05/2022 - 09/2014
16Adrenal Cortex Hormones (Corticosteroids)IBA
01/2021 - 09/2007
15Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2022 - 10/2008
14Bevacizumab (Avastin)FDA Link
05/2022 - 09/2014
13Triamcinolone (Aristocort)FDA Link
02/2011 - 07/2004
7Ranibizumab (Lucentis)FDA Link
03/2022 - 09/2012
7Valsartan (Vals)FDA Link
01/2022 - 05/2017
7Fluorescein (Funduscein)FDA LinkGeneric
01/2022 - 09/2010
6Triamcinolone Acetonide (Azmacort)FDA LinkGeneric
09/2015 - 09/2002
3Biomarkers (Surrogate Marker)IBA
12/2022 - 01/2020
3Propranolol (Inderal)FDA LinkGeneric
01/2018 - 03/2013
2salicylhydroxamic acid (SHAM)IBA
03/2022 - 09/2012
1Retinal Pigments (Pigments, Visual)IBA
10/2021
12- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
07/2021
1Indicators and Reagents (Reagents)IBA
01/2021
1EndotoxinsIBA
09/2019
1Pharmaceutical PreparationsIBA
05/2017
1Adrenergic Agents (Adrenergic Drugs)IBA
03/2013
1Niacin (Nicotinic Acid)FDA LinkGeneric
01/2011
1Silicone OilsIBA
11/2009

Therapy/Procedure

12Therapeutics
03/2022 - 01/2004
6Injections
03/2022 - 09/2007
6Lasers (Laser)
01/2017 - 12/2008
6Light Coagulation
02/2011 - 07/2008
5Intravitreal Injections
09/2012 - 07/2004
3Aftercare (After-Treatment)
01/2022 - 01/2019
3Drug Therapy (Chemotherapy)
10/2016 - 10/2008
2Laser Therapy (Surgery, Laser)
12/2021 - 12/2009
1Intraocular Injections
03/2022
1Intraperitoneal Injections
03/2013
1Vitrectomy
09/2010
1Glycemic Control
07/2008
1Antibiotic Prophylaxis
09/2007